The dark side of ecstasy: Neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 1, 2008, Pages 15-24

  Karlsen, Sunniva Nyberg ^a   Spigset, Olav ^a,b   Slørdal, Lars ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 DIHYDROXYAMPHETAMINE; 3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ILLICIT DRUG; UNCLASSIFIED DRUG;

AMNESIA; COGNITION; COGNITIVE DEFECT; CORRELATION ANALYSIS; DRUG EFFECT; DRUG WITHDRAWAL; EXPOSURE; HUMAN; LONGITUDINAL STUDY; MENTAL DISEASE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; SYMPTOMATOLOGY;

ANIMALS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HALLUCINOGENS; HUMANS; MENTAL DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

ANIMALIA;

EID: 37349131558     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00159.x     Document Type: Short Survey

References (117)

1. Freudenmann RW, Øxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction 2006 101 : 1241 5.
2. Sternbach GL, Varon J. Designer drugs. Postgrad Med 1992 91 : 169 76.
3. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986 18 : 335 40.
4. Parrott AC. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001 16 : 557 77.
5. Greer GR, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986 18 : 319 27.
6. Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 2004 173 : 234 41.
7. Sessa B. Is there a case for MDMA-assisted psychotherapy in the UK? J Psychopharmacol 2007 21 : 220 4.
8. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 2005 5 : 79 86.
9. Bobes J, Sáiz PA, González MP et al. Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study. Eur Addict Res 2002 8 : 147 54.
10. Tossmann P, Boldt S, Tensil MD. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 2001 7 : 2 23.
11. de la Torre R, Farre M, Ortuno J et al. Non-linear pharmacokinetics of MDMA (ecstasy) in humans. Br J Clin Pharmacol 2000 49 : 104 9.
12. Evanko D. Designer drugs. Postgrad Med 1991 89 : 69 71.
13. Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs 1986 18 : 291 304.
14. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999 55 : 105 15.
15. Spitzer M, Franke B, Walter H et al. Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neurophramacology 2001 41 : 263 71.
16. de la Torre R, Farré M, Roset PN et al. Human pharmacology of MDMA. Pharmacokinetics, metabolism, and disposition. Ther Drug Monit 2004 26 : 137 44.
17. Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology 2004 173 : 242 8.
18. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001 64 : 9 17.
19. Wish ED, Fitzelle DB, O'Grady KE, Hsu MH, Arria AM. Evidence for significant polydrug use among ecstasy-using college students. Am J Coll Health 2006 55 : 99 104.
20. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 2001 16 : 589 98.
21. de la Torre R, Farré M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 2004 25 : 505 8.
22. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002 53 : 111 22.
23. Yang J, Jamei M, Heydari A et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 2006 20 : 842 9.
24. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002 95 : 73 88.
25. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000 22 : 513 21.
26. Parrott AC. Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 2005 19 : 71 83.
27. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology 1995 119 : 247 60.
28. Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA ('ecstasy') after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 2000 10 : 289 95.
29. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988 1 : 273 7.
30. Farré M, de la Torre R, Mathúna BÓ et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 2004 173 : 364 75
31. Baylen CA, Rosenberg H. A review of the acute subjective effects of MDMA/ecstasy. Addiction 2006 101 : 933 47.
32. Steele TD, McCann UD, Ricaurte GA. 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): pharmacology and toxicology in animals and humans. Addiction 1994 89 : 539 51.
33. Davison D, Parrott AC. Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 1997 12 : 221 26.
34. Freedman RR, Johanson CE, Tancer ME. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Pscychopharmacology 2005 183 : 248 56.
35. Roberts L, Wright H. Survival following intentional massive overdose of ecstasy. J Accid Emerg Med 1993 11 : 53 4.
36. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998 12 : 482 91.
37. Henry JA, Jeffereys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 1992 340 : 384 7.
38. Liechti ME, Kunz I, Kupferschmidt H. Acute medical problems due to ecstasy use. Swiss Med Wkly 2005 135 : 652 7.
39. Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) ingestion. Q J Med 2002 95 : 431 7.
40. Schifano F, Oyefeso A, Corkery J et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol 2003 18 : 519 24.
41. Vuori E, Henry JA, Ojanperä I et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003 98 : 365 68.
42. Bond AJ. Antidepressant treatment and human aggression. Eur J Pharmacol 2005 526 : 218 55.
43. Parrot AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 1998 139 : 261 8.
44. Verheyden SL, Hadfield J, Calin T et al. Sub-acute effects of MDMA (3,4-methylenedioxymethamphetamine, ecstasy) on mood: evidence of gender differences. Psychopharmacology 2002 161 : 23 31.
45. Curran HV, Travill RA. Mood and cognitive effects of 3,4- methylenedioxymethamphetamine (MDMA, ecstasy): week-end 'high' followed by mid-week low. Addiction 1997 92 : 821 31.
46. Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term subjective consequences of ecstasy (MDMA) consumption in 430 regular users. Hum Psychopharmacol 2003 18 : 507 17.
47. Verheyden SL, Maidment R, Curran HV. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol 2003 17 : 371 8.
48. Sprague JE, Nichols DE. Neurotoxicity of MDMA (ecstasy): beyond metabolism. Trends Pharamol Sci 2005 26 : 59 60.
49. Parrott AC. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004 50 : 329 35.
50. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999 19 : 5096 107.
51. Kish SJ. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 2002 71 : 845 55.
52. Parrott AC. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002 71 : 837 44.
53. Obrocki J, Schmoldt A, Buchert R, Andresen B, Petersen K, Thomasius R. Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett 2002 127 : 285 97.
54. Curran HV. Is MDMA (ecstasy) a neurotoxin in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 2000 42 : 34 41.
55. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (±) 3,4-methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol 1991 11 : 302 5.
56. Fox HC, Parrott AC, Turner JJD. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 2001 15 : 273 81.
57. Thomasius R, Petersen K, Buchert R et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 2003 167 : 85 96.
58. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) users: a controlled study. Psychopharmacology 1999 143 : 417 25.
59. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA (ecstasy) users. Neurology 1998 51 : 1532 7.
60. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in ecstasy users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology 2000 148 : 322 4.
61. Verkes RJ, Gijsman HJ, Pieters MSM et al. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 2001 153 : 196 202.
62. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 2004 173 : 434 9.
63. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992 18 : 331 41.
64. Morgan MJ. Memory deficits associated with recreational use of ecstasy (MDMA). Psychopharmacology 1999 141 : 30 6.
65. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K. Cognitive performance in recreational users of MDMA or ecstasy: evidence for memory deficits. J Psychopharmacol 1998 12 : 79 8.
66. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000 68 : 719 25.
67. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JG. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 2001 153 : 373 79.
68. Curran HV, Verheyden SL. Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacology 2003 169 : 91 103.
69. Fisk JE, Montgomery C, Murphy P, Wareing M. Evidence for executive deficits among users of MDMA (ecstasy). Br J Psychology 2004 95 : 457 66.
70. Moeller FG, Steinberg JL, Dougherty DM, Narayana PA, Kramer LA, Renshaw PF. Functional MRI study of working memory in MDMA users. Psychopharmacology 2004 177 : 185 94.
71. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J. Prospective memory, everyday cognitive failure and central executive function in recreational users of ecstasy. Hum Psychopharmacol 2001 16 : 607 12.
72. Heffernan TM, Ling J, Scholey AB. Subjective ratings of prospective memory deficits in MDMA (ecstasy) users. Hum Psychopharmacol 2001 16 : 339 44.
73. Fox HC, Toplis AS, Turner JJ, Parrott AC. Auditory verbal learning in drug-free ecstasy polydrug users. Hum Psychopharmacol 2001 16 : 613 8.
74. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 2003 27 : 819 27.
75. Halpern JH, Pope HG Jr., Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D. Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004 75 : 135 47.
76. Semple DM, Ebmeier KP, Glabus MF, O'Careroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (ecstasy) users. Br J Psychiatry 1999 175 : 63 9.
77. Gouzoulis-Mayfrank E, Fischermann T, Rezk M, Thimm B, Hensen G, Daumann J. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug Alcohol Depend 2005 78 : 317 23.
78. Zakzanis KK, Young DA. Memory impairment in abstinent MDMA (ecstasy) users: a longitudinal investigation. Neurology 2001 56 : 966 9.
79. Zakzanis KK, Campbell Z. Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 2006 66 : 740 1.
80. Dafters RI, Hoshi R, Talbot AC. Contribution of cannabis and MDMA (ecstasy) to cognitive changes in long-term polydrug users. Psychopharmacology 2004 173 : 405 10.
81. Simon NG, Mattick RP. The impact of regular ecstasy use on memory function. Addiction 2002 97 : 1523 9.
82. Rodgers J. Cognitive performance amongst recreational users of ecstasy. Psychopharmacology 2000 151 : 19 24.
83. Morgan MJ, McFie L, Fleetwood LH, Robinson JA. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 2002 159 : 294 303.
84. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC. Differential effects of ecstasy and cannabis on self-reports of memory ability: a web-based study. Hum Psychopharmacol 2001 16 : 619 25.
85. Heffernan TM, Ling J, Scholey AB. Subjective ratings of prospective memory deficits in MDMA ('ecstasy') users. Hum Psychopharmacol 2001 16 : 339 44.
86. Parrott AC, Sisk E, Turner JJD. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 2000 60 : 105 10.
87. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA ('ecstasy'). Br J Psychology 2000 91 : 181 8.
88. Dafters RL, Duffy F, O'Donnell PJ, Bouquet C. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology 1999 145 : 82 90.
89. Verbaten MN. Specific memory deficits in ecstasy users? The results of a meta-analysis. Hum Psychopharmacol 2003 18 : 281 90.
90. Bhattachary S, Powell JH. Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or ecstasy: evidence for cognitive impairment. Psychol Med 2001 31 : 647 58.
91. Schifano F, Magni G. MDMA (ecstasy) abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiatry 1994 36 : 763 7.
92. Creighton FJ, Black DL, Hyde CE. 'Ecstasy' psychosis and flashbacks. Br J Psychiatry 1991 159 : 713 5.
93. Williams H, Meagher D, Galligan P. MDMA (ecstasy); a case of possible drug-induced psychosis. Ir J Med Sci 1993 162 : 43 4.
94. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (ecstasy). Br J Psychiatry 1994 165 : 91 5.
95. McCann UD, Ricaurte GA. MDMA (ecstasy) and panic disorder: induction by a single dose. Biol Psychiatry 1992 32 : 950 3.
96. Pallanti S, Mazzi D. MDMA (ecstasy) precipitation of panic disorder. Biol Psychiatry 1992 32 : 91 5.
97. Whitaker-Azmitia PM, Aronson TA. Ecstasy (MDMA)-induced panic. Am J Psychiatry 1989 146 : 119.
98. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 2002 68 : 195 207.
99. Huizink AC, Fredinand RF, van der Ende J, Verhulst FC. Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 2006 332 : 825.
100. Soar K, Turner JJD, Parrott AC. Psychiatric disorders in ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum Psychopharmacol 2001 16 : 641 45.
101. Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology 2004 173 : 398 404.
102. Parrot AC, Milani RM, Parmar R, Turner JD. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001 159 : 77 82.
103. 15O] positron emission tomography study. J Clin Psychopharmacol 2001 21 : 66 71.
104. de Win MML, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W. Mood disorders and serotonin transporter density in ecstasy users - the influence of long-term abstention, dose, and gender. Psychopharmacology 2004 173 : 376 82.
105. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R. Serotonergic function after (+/-) 3,4-methylenedioxymethamphetamine ('ecstasy') in humans. Int Clin Psychopharmacol 1998 13 : 1 19.
106. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002 17 : 309 12.
107. MacInnes N, Handley SL, Harding GFA. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 2001 15 : 181 6.
108. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E. Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol 2001 16 : 627 33.
109. Bond AJ, Verheyden SL, Wingrove J, Curran HV. Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacology 2004 171 : 331 39.
110. Dughiero G, Schifano F, Forza G. Personality dimensions and psychophatological profiles of ecstasy users. Hum Psychopharmacol 2001 16 : 635 9.
111. Morgan MJ. Recreational use of ecstasy (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998 19 : 252 64.
112. Klugman A, Hardy S, Baldeweg T, Gruzelier J. Toxic effect of MDMA on brain serotonin neruons. Lancet 1999 353 1269 70.
113. Sumnall HR, Cole JC. Self-reported depressive symptomatology in community samples of polysubstance misusers who report ecstasy use: a meta-analysis. J Psychopharmacol 2005 19 : 89 97.
114. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA (ecstasy) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 1998 52 : 85 90.
115. Milani RM, Parrott AC, Turner JJ, Fox HC. Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav 2004 29 : 965 71.
116. Milani RM, Parrott AC, Schifano F, Turner JJ. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum Psychopharmacol 2005 20 249 61.
117. Anonymus. Ecstacy's after-effects. Nature 2003 425 : 223.